ERBB2 and lung cancer: Except six patients with unknown histology and one patient with mixed ADC and SCC, all patients with ERBB2 TMD mutations were ADCs at a frequency of 0.17% (38 out of 21 762), consistent with the previous report in western lung cancer patients (Ou et al., 2017).